



Sample Information

Patient Name: 林家祥
Gender: Male
ID No.: A110515279
History No.: 32696643
Age: 65

Ordering Doctor: DOC1322F 趙毅
Ordering REQ.: H3LMM45
Signing in Date: 2021/12/03

Path No.: S110-94702
MP No.: TM21013
Assay: Oncomine Tumor Mutation Load Assay
Sample Type: FFPE
Block No.: S110-77291B
Percentage of tumor cells: 80%

Reporting Doctor: DOC5466K 葉奕成 (Phone: 8#5466)

Note:

Sample Cancer Type: Cholangiocarcinoma

Table of Contents	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	3
Relevant Therapy Summary	4
Relevant Therapy Details	5
Prognostic Details	12
Clinical Trials Summary	13
Alert Details	13

Report Highlights
2 Relevant Biomarkers
2 Therapies Available
3 Clinical Trials

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	<i>Tumor Mutational Burden</i> 0.0 Mut/Mb measured Prognostic significance: None Diagnostic significance: None	pembrolizumab ¹	pembrolizumab	2

Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO

Public data sources included in prognostic and diagnostic significance: NCCN, ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Relevant Biomarkers (continued)

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	IDH1 p.(R132H) c.395G>A isocitrate dehydrogenase (NADP(+)) 1 Allele Frequency: 22.32% Prognostic significance: NCCN: Poor Diagnostic significance: None	ivosidenib	None	1

Public data sources included in relevant therapies: FDA1, NCCN, EMA2, ESMO

Public data sources included in prognostic and diagnostic significance: NCCN, ESMO

Tier Reference: Li et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 Jan;19(1):4-23.

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
IDH1	p.(R132H)	c.395G>A	COSM28746	chr2:209113112	22.32%	NM_005896.3	missense	1994
PIK3CD	p.(P2S)	c.4C>T	.	chr1:9770517	64.36%	NM_005026.4	missense	1981
PDE4DIP	p.(V1831M)	c.5491G>A	.	chr1:144867948	20.50%	NM_001198834.3	missense	2000
ABL2	p.(G729E)	c.2186G>A	.	chr1:179078171	4.49%	NM_005158.4	missense	89
LTF	p.(R23dup)	c.68_69insAAG	.	chr3:46501284	100.00%	NM_002343.5	nonframeshift Insertion	1946
PDGFRA	p.(=)	c.1701A>G	.	chr4:55141055	99.80%	NM_006206.5	synonymous	1983
AFF1	p.(D18Y)	c.52G>T	.	chr4:87967331	49.55%	NM_001166693.2	missense	1998
APC	p.(A735V)	c.2204C>T	.	chr5:112173495	50.00%	NM_000038.5	missense	2000
NSD1	p.(=)	c.1317C>T	.	chr5:176636717	51.08%	NM_022455.4	synonymous	1999
NOTCH4	p.(D272G)	c.813_815delAGAGins GGG	.	chr6:32188640	49.77%	NM_004557.3	synonymous, missense	1989
EPHA7	p.(A661S)	c.1981G>T	.	chr6:93967946	34.85%	NM_004440.3	missense	1997
SYNE1	p.(K4121S)	c.12362_12363delAGinsGT	.	chr6:152658141	46.39%	NM_182961.3	missense	1996
SYNE1	p.(K4121R)	c.12362A>G	.	chr6:152658142	51.30%	NM_182961.3	missense	1996
WRN	p.(R711P)	c.2132G>C	.	chr8:30969174	48.55%	NM_000553.4	missense	1998
KAT6A	p.(E1109del)	c.3326_3328delAAG	.	chr8:41794797	50.61%	NM_006766.4	nonframeshift Deletion	1980
RUNX1T1	p.(=)	c.1446G>A	.	chr8:92983012	47.22%	NM_001198634.1	synonymous	1421
FANCC	p.(R532K)	c.1595G>A	.	chr9:97864071	50.09%	NM_000136.2	missense	1747
NUP214	p.(=)	c.3477T>C	.	chr9:134062733	49.57%	NM_005085.3	synonymous	1612
NUP214	p.(=)	c.4926A>G	.	chr9:134073807	49.40%	NM_005085.3	synonymous	1836
TSC1	p.(S487C)	c.1460C>G	.	chr9:135781505	50.08%	NM_000368.4	missense	1997
RET	p.(V292M)	c.874G>A	.	chr10:43601830	49.73%	NM_020975.4	missense	1498

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency) (continued)

DNA Sequence Variants (continued)

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
KAT6B	p.(E1079_E1082del)	c.3252_3263delGGA AGAAGAGGA	.	chr10:76781851	22.09%	NM_012330.3	nonframeshift Deletion	
KMT2D	p.(G794E)	c.2381G>A	.	chr12:49445085	9.62%	NM_003482.3	missense	52
KMT2D	p.(=)	c.2379G>A	.	chr12:49445087	9.62%	NM_003482.3	synonymous	52
TRIP11	p.(R1752K)	c.5255G>A	.	chr14:92454633	20.15%	NM_004239.4	missense	1712
TRIP11	p.(E506A)	c.1517A>C	.	chr14:92473994	33.48%	NM_004239.4	missense	1998
CDH2	p.(=)	c.1104C>T	.	chr18:25573518	50.73%	NM_001792.4	synonymous	1999

Biomarker Descriptions

IDH1 (isocitrate dehydrogenase (NADP(+)) 1)

Background: The IDH1 and IDH2 genes encode homologous isocitrate dehydrogenase enzymes that catalyze the conversion of isocitrate to α -ketoglutarate (α -KG)¹. The IDH1 gene encodes the NADP+ dependent cytoplasmic isocitrate dehydrogenase enzyme; IDH2 encodes the mitochondrial isoform.

Alterations and prevalence: Recurrent somatic mutations in IDH1 and IDH2 are mutually exclusive and observed in several malignancies including glioma, chondrosarcoma, intrahepatic cholangiocarcinoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS)². Recurrent IDH1 variants include predominately R132H/C plus other substitutions at lower frequencies. These gain of function variants confer neomorphic enzyme activity³. Although wild-type enzymatic activity is ablated, recurrent IDH1 variants catalyze the conversion of α -KG to D-2-hydroxyglutarate, an oncometabolite with diverse effects on cellular metabolism, epigenetic regulation, redox states, and DNA repair^{1,4}. Recurrent IDH1 mutations are present in 5-10% of patients with AML and 5% of patients with MDS^{5,6,7}. Recurrent IDH1 mutations are present in nearly 80% of lower grade gliomas^{8,9}.

Potential relevance: Ivosidenib¹⁰ is FDA approved (2018) for the treatment of AML patients with IDH1 R132C/G/H/L/S variants¹¹. Ivosidenib has also been granted breakthrough designation (2020) for IDH1 mutated relapsed or refractory myelodysplastic syndrome (MDS)¹². IDH1 mutations are associated with inferior leukemia-free survival in primary myelofibrosis (PMF) and inferior overall survival in polycythemia vera (PV) but have been shown to confer improved prognosis in lower grade gliomas^{13,14,15}.

Tumor Mutational Burden

Background: Tumor mutational burden (TMB), also known as tumor mutational load (TML), is the count of somatic mutations in the DNA of cancer cells. TMB is determined by next-generation sequencing and is expressed as the number of mutations per megabase (mut/Mb) of DNA coding sequence¹⁶. Errors in DNA repair, including mutations in the POLE gene and in mismatch repair (MMR) genes, are associated with increased TMB^{17,18,19,20,21}. High TMB is associated with increased neo-antigen burden and has been linked to response to immune checkpoint inhibitors (ICIs) that target the cytotoxic T lymphocyte antigen-4 (CTLA4), programmed death protein 1 (PD1), and programmed death-ligand 1 (PD-L1) inhibitors^{22,23,24,25}.

Alterations and prevalence: In one study of over 100,000 tumor samples, the median TMB value was 3.6 mut/Mb although TMB values vary widely across cancers²⁶. Certain childhood cancers, leukemia, glioblastoma, and neuroblastoma typically have low mutation burden and median TMB values <1 mut/Mb^{23,26}. In comparison, cancers that experience genotoxic insults including skin cancer and lung cancer have higher median TMB values of approximately 10 mut/Mb^{23,26}. For example, within non-small cell lung cancer (NSCLC), higher TMB was observed in former/current smokers (10.5 mut/Mb) relative to never smokers (0.6 mut/Mb)^{23,26,27}. There is no consensus around the definition of high and low TMB that could be applied universally to all tumor types, instead multiple sources suggest that TMB status is a cancer type specific attribute^{26,28,29}. In NSCLC, several studies have suggested establishing a threshold between low and high TMB of 10 +/- 1 mut/Mb^{30,31,32,33}.

Potential relevance: ICIs stimulate a patient's own T-cells to kill tumors and have exhibited benefits in some patients. The first ICI to be approved by the FDA was ipilimumab (2011), an anti-CTLA4 antibody indicated for the treatment of metastatic melanoma. In 2014, anti-PD-1 antibodies, nivolumab (2014) and pembrolizumab (2014), were subsequently approved for the treatment of metastatic melanoma. Pembrolizumab was also approved (2014) for advanced esophageal squamous cell carcinoma. In 2020, the indication for pembrolizumab³⁴ was expanded to include TMB-H (≥ 10 mut/Mb) solid tumors that have progressed on prior therapy. Indications

Biomarker Descriptions (continued)

have been expanded for these ICIs to include several other cancer types including NSCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability (MSI)-High or mismatch repair deficient (dMMR) colorectal cancer, and hepatocellular carcinoma. Atezolizumab (2016), avelumab (2017), and durvalumab (2017), that target programmed death-ligand 1 (PD-L1), were subsequently approved by the FDA. However, the predictive biomarkers that underlie the clinical benefits of these approved immunotherapies, including TMB, are under active investigation. Several published studies including the CheckMate 586 and CheckMate 817 clinical trials have concluded that high TMB was associated with improved response to FDA approved checkpoint inhibitors^{31,35,36}. In contrast, several promising previous trials failed to show an improvement in survival outcomes between high and low TMB including CheckMate 227 (ipilimumab + nivolumab vs. chemotherapy), CheckMate 026 (nivolumab vs. chemotherapy), KEYNOTE 189 (pembrolizumab vs. chemotherapy), KEYNOTE 021 (pembrolizumab vs. pembrolizumab + chemotherapy), and Lung-MAP (nivolumab + ipilimumab vs. nivolumab). In response, suggestions to combine TMB score with PD-L1 expression as a way to increase the predictive power for patient stratification have been reported³⁷. Nivolumab alone or in combination with ipilimumab is recommended for use in NSCLC with evidence of high TMB³⁸. Pembrolizumab is indicated for use in various cancer types with evidence of metastasis including Ewing sarcoma, salivary gland neoplasms, cervical cancer, uterine sarcoma, endometrial carcinoma, thyroid cancer, ovarian cancer, esophageal cancer, esophagogastric junction cancer, breast cancer, and germ cell tumors with high TMB^{39,40,41,42,43,44,45,46,47}. TMB score estimation is affected by the utilized assays, therefore efforts are underway to develop a standardized approach for score calculation with the aim to support consistent reporting of TMB values across laboratories^{48,49,50,51}.

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

Tumor Mutational Burden

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pembrolizumab	●	●	×	×	● (II)
atezolizumab	×	×	×	×	● (II)

IDH1 p.(R132H) c.395G>A

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
ivosidenib	×	●	×	×	×
LY-3410738	×	×	×	×	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2021-08-18. For the most up-to-date information, search www.fda.gov.

Tumor Mutational Burden

● pembrolizumab

Cancer type: Solid Tumor

Label as of: 2021-08-10

Variant class: Tumor Mutational Burden

Indications and usage:

KEYTRUDA® is a programmed death receptor-1 (PD-1)-blocking antibody indicated:

Melanoma

- for the treatment of patients with unresectable or metastatic melanoma.
- for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer (NSCLC)

- in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) $\geq 1\%$] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
 - stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
 - metastatic.
- as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS $\geq 1\%$) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA®.

Head and Neck Squamous Cell Cancer (HNSCC)

- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test.
- as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma (cHL)

- for the treatment of adult patients with relapsed or refractory cHL.
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.
- Limitations of Use: KEYTRUDA® is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.¹

Tumor Mutational Burden (continued)

- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

- for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.¹
- Limitations of Use: The safety and effectiveness of KEYTRUDA® in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)

- for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

- in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.¹
- as a single agent for the treatment of patients with recurrent locally advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test, with disease progression on or after 2 or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.¹

Esophageal Cancer

- for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
 - in combination with platinum- and fluoropyrimidine-based chemotherapy, or
 - as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥ 10) as determined by an FDA-approved test.

Cervical Cancer

- for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test.¹

Hepatocellular Carcinoma (HCC)

- for the treatment of patients with HCC who have been previously treated with sorafenib.¹

Merkel Cell Carcinoma (MCC)

- for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.¹

Renal Cell Carcinoma (RCC)

- in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
- in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.

Endometrial Carcinoma

- in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Tumor Mutational Burden-High (TMB-H) Cancer

- for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.¹
- Limitations of Use: The safety and effectiveness of KEYTRUDA® in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma (cSCC)

Tumor Mutational Burden (continued)

- for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.

Triple-Negative Breast Cancer (TNBC)

- for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA approved test.

Adult Indications: Additional Dosing Regimen of 400 mg Every 6 Weeks

- for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications.²

¹This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

²This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s102lbl.pdf

Current NCCN Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2021-08-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

Tumor Mutational Burden

☒ pembrolizumab

Cancer type: Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma
Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

☐ pembrolizumab

Cancer type: Chondrosarcoma, Osteosarcoma
Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Bone Cancer [Version 1.2022]

☐ pembrolizumab

Cancer type: Breast Cancer
Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IV; Recurrent, Invasive, Unresectable, Local (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Breast Cancer [Version 5.2021]

☐ pembrolizumab

Cancer type: Cervical Cancer
Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Metastatic, Progression (Second-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2021]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Esophageal Cancer,
Gastroesophageal Junction Adenocarcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Squamous Cell; Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 3.2021]

○ pembrolizumab

Cancer type: Gastric Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Gastric Cancer [Version 3.2021]

○ pembrolizumab

Cancer type: Head and Neck Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Nasopharyngeal; Recurrent, Unresectable, Metastatic (Subsequent therapy); Useful in certain circumstances
- Salivary Gland Neoplasm; Recurrent, Unresectable, Metastatic (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2021]

○ pembrolizumab

Cancer type: Ovarian Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Epithelial, Less Common Ovarian Cancers, Fallopian Tube, Primary Peritoneal; Recurrent (Recurrence therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2021]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Testicular Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Germ Cell Tumor; Metastatic (Third-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Testicular Cancer [Version 2.2021]

○ pembrolizumab

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Locally Recurrent, Advanced, Metastatic (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

○ pembrolizumab

Cancer type: Thyroid Gland Medullary Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Persistent, Local, Distant Metastases (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

○ pembrolizumab

Cancer type: Thyroid Gland Anaplastic Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IVC; Metastatic (Second-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Endometrial Carcinoma, Uterine Sarcoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Metastatic (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 3.2021]

○ pembrolizumab

Cancer type: Ewing Sarcoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Metastatic (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Bone Cancer [Version 1.2022]

IDH1 p.(R132H) c.395G>A

● ivosidenib

Cancer type: Extrahepatic Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma

Variant class: IDH1 mutation

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

Prognostic Details

Current NCCN Information

NCCN information is current as of 2021-08-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

IDH1 p.(R132H) c.395G>A

Prognostic significance: NCCN: Poor

Cancer type: Extrahepatic Cholangiocarcinoma

Variant class: IDH1 mutation

NCCN Recommendation category: 2A

Summary:

- NCCN® associates the biomarker with poor prognosis

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

Clinical Trials in Taiwan region:

Clinical Trials Summary

Tumor Mutational Burden

NCT ID	Title	Phase
NCT04589845	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	II
NCT02628067	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	II

IDH1 p.(R132H) c.395G>A

NCT ID	Title	Phase
NCT04521686	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations.	I

Alerts Informed By Public Data Sources

Current NCCN Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

NCCN information is current as of 2021-08-02. For the most up-to-date information, search www.nccn.org. For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

Tumor Mutational Burden

pembrolizumab

Cancer type: Giant Cell Tumor of Soft Tissue

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "NCCN does not recommend this systemic treatment for GCTB since it is not technically a malignant tumor."

Reference: NCCN Guidelines® - NCCN-Bone Cancer [Version 1.2022]

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. Molenaar et al. Wild-type and mutated IDH1/2 enzymes and therapy responses. *Oncogene*. 2018 Apr;37(15):1949-1960. PMID: 29367755
2. Yan et al. IDH1 and IDH2 mutations in gliomas. *N. Engl. J. Med.* 2009 Feb 19;360(8):765-73. PMID: 19228619
3. Dang et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*. 2009 Dec 10;462(7274):739-44. PMID: 19935646
4. Ward et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell*. 2010 Mar 16;17(3):225-34. PMID: 20171147
5. Paschka et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J. Clin. Oncol.* 2010 Aug 1;28(22):3636-43. PMID: 20567020
6. Chou et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. *Leukemia*. 2011 Feb;25(2):246-53. PMID: 21079611
7. Marcucci et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J. Clin. Oncol.* 2010 May 10;28(14):2348-55. PMID: 20368543
8. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
9. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf
11. Abou et al. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. *Ther Adv Hematol.* 2018 Jul;9(7):163-173. PMID: 30013764
12. <https://investor.agios.com/news-releases/news-release-details/agios-receives-fda-breakthrough-therapy-designation-tibsovor-0>
13. NCCN Guidelines® - NCCN-Myeloproliferative Neoplasms [Version 1.2021]
14. Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med.* 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10. PMID: 26061751
15. Houillier et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. *Neurology*. 2010 Oct 26;75(17):1560-6. PMID: 20975057
16. Yuan et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 4:3. PMID: 26788324
17. Temko et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. *J. Pathol.* 2018 Jul;245(3):283-296. PMID: 29604063
18. Mehnert et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. 126(6):2334-40. PMID: 27159395
19. Bouffet et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *J. Clin. Oncol.* 2016 Jul 1;34(19):2206-11. PMID: 27001570
20. Humphris et al. Hypermutation In Pancreatic Cancer. *Gastroenterology*. 2017 Jan;152(1):68-74.e2. PMID: 27856273
21. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol.* 2017;2017. PMID: 29850653
22. Snyder et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N. Engl. J. Med.* 2014 Dec 4;371(23):2189-2199. PMID: 25409260
23. Alexandrov et al. Signatures of mutational processes in human cancer. *Nature*. 2013 Aug 22;500(7463):415-21. PMID: 23945592
24. Rizvi et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015 Apr 3;348(6230):124-8. PMID: 25765070
25. Van et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science*. 2015 Oct 9;350(6257):207-211. PMID: 26359337
26. Chalmers et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. 9:34. PMID: 28420421
27. Govindan et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. *Cell*. 2012 Sep 14;150(6):1121-34. PMID: 22980976
28. Endris et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. *Int. J. Cancer*. 2019 May 1;144(9):2303-2312. PMID: 30446996

References (continued)

29. Meléndez et al. Methods of measurement for tumor mutational burden in tumor tissue. *Transl Lung Cancer Res.* 2018 Dec;7(6):661-667. PMID: 30505710
30. Hellmann et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. *N. Engl. J. Med.* 2018 May 31;378(22):2093-2104. PMID: 29658845
31. Ready et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. *J. Clin. Oncol.* 2019 Apr 20;37(12):992-1000. PMID: 30785829
32. Alborelli et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. *J. Pathol.* 2020 Jan;250(1):19-29. PMID: 31471895
33. Heeke et al. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. *Cancers (Basel).* 2019 Aug 29;11(9). PMID: 31470674
34. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s102lbl.pdf
35. F. et al. CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC. Volume 14, Issue 10, Supplement, Pages S214–S215. Abstract OA04.02
36. Zhu et al. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. *Front Oncol*, 9:1161, 04 Nov 2019. PMID: 31258479
37. Castellanos et al. Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. *Journal of Clinical Oncology* 37, no. 15_suppl (May 20, 2019) 2630-2630. Abstract 2630
38. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2021]
39. NCCN Guidelines® - NCCN-Bone Cancer [Version 1.2022]
40. NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2021]
41. NCCN Guidelines® - NCCN-Testicular Cancer [Version 2.2021]
42. NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2021]
43. NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 3.2021]
44. NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]
45. NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 3.2021]
46. NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2021]
47. NCCN Guidelines® - NCCN-Breast Cancer [Version 5.2021]
48. <https://www.focr.org/tmb>
49. <http://www.iqnpaath.org/category/tmb>
50. Stenzinger et al. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. *Genes Chromosomes Cancer.* 2019 Aug;58(8):578-588. PMID: 30664300
51. Merino et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. *J Immunother Cancer.* 2020 Mar;8(1). PMID: 32217756